Swiss pharmaceutical giant Novartis International AG (NYSE: NVS) on Friday said its ofatumumab met the primary and secondary endpoints of Phase 3 clinical trials for the treatment of multiple sclerosis.
The trials demonstrated the therapy’s efficacy in reducing the number of confirmed relapses as well as delaying disability progression.
The drug, which has already received approval for the treatment of chronic lymphocytic leukemia, could boost overall sales once approved for multiple sclerosis also.
The company said it would initiate submissions to health authorities by the end of this year.
“Ofatumumab, if approved, could be a highly attractive treatment option for a broad RMS patient population, including early MS,” said John Tsai, Head Global Drug Development and Chief Medical Officer, Novartis. “The powerful study results are a reflection of our commitment to reimagine MS treatment at all stages of the disease.”
Earlier this year, Novartis had won an FDA approval for Mayzent, a drug used for patients suffering from active secondary progressive multiple sclerosis.
Novartis shares gained 1.6% during pre-market trading on Friday. The stock has jumped 22% since the beginning of this year.
New threat to Sanofi, Roche
The latest development is set to pit Novartis directly against Sanofi SA (NASDAQ: SNY) and Roche in the multiple sclerosis realm. Novartis said the clinical trials showed that its drug had superior efficacy when compared with Sanofi’s treatment teriflunomide (Aubagio).
However, teriflunomide is a smaller player in terms of sales, and Novartis’ primary competition would be with Roche’s blockbuster drug ocrevus. Notably, ocrevus is the solo approved therapy for the treatment of primary progressive multiple sclerosis.
SNY shares were trading down 0.12% during pre-market trading hours.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Infographic: How Lennar (LEN) performed in Q4 2025
Lennar Corporation (NYSE: LEN) reported total revenues of $9.4 billion for the fourth quarter of 2025, compared to $9.9 billion reported in the same period a year ago. Net earnings
Paychex expected to report higher revenue and earnings for Q2 FY26
Paychex, Inc. (NASDAQ: PAYX), a leading provider of human capital management solutions, is undergoing an AI-driven transformation that enhances both its internal operations and client-facing services. Entering fiscal 2026, the
Signet Jewelers (SIG): A look at the progress made on Grow Brand Love
Shares of Signet Jewelers Limited (NYSE: SIG) fell over 3% on Tuesday. The stock has gained 3% year-to-date. The jewelry retailer delivered strong results for the third quarter of 2026,
